KIT Specific Neutra™ Antibody Products

Product list

KIT Proto-Oncogene, Receptor Tyrosine Kinase, also known as SCFR or CD117, is a vital member of the cytokine receptor family. The typical form of the protein has an N-terminal extracellular domain, a special C-terminal intracellular domain as well as a transmembrane domain. After activation by specific factors, this protein will phosphorylate a variety of intracellular proteins, thereby participating in cell proliferation, migration, and apoptosis. Mutations in the KIT gene may lead to the occurrence of a variety of diseases, such as mast cell disease, thymic cancer, acute myeloid leukemia, gastrointestinal stromal tumors, leiomyosarcoma, and piebaldism.

Its Gene ID: 3815, UniProtKB ID: P10721, and OMIM ID: 164920.

Fig.1 KIT structure diagram. Fig.1 Schematic representation of the structure of KIT.^1,3

Functions

KIT has been found to be expressed on the surface of bone marrow-derived stem cells as well as on stem cells in other organs, such as the heart and liver. These shreds of evidence reveal that the KIT signaling pathway may be involved in the stemness regulation of some organs. In addition, it has been reported that KIT is a crucial regulator of various life activities, such as cell survival, mast cell development, gametogenesis, and melanin production. Furthermore, KIT signaling is involved in regulating oogenesis and spermatogenesis. Therefore, it is closely associated with female and male fertility.

KIT Signaling Pathways

KIT can activate multiple signaling pathways. KIT participates in the activation of the AKT1 signaling pathway through phosphorylation of PIK3R1. Furthermore, KIT contributes to the activation of multiple transcription factors, including STAT1, STAT3, STAT5A, and STAT5B. It is worth noting that activated KIT further performs signal transduction by regulating the activation of MAPK1/ERK2 or MAPK3/ERK1.

Fig.2 KIT related pathways. Fig.2 Intracellular signaling pathways that KIT is involved in.^2,3

Anti-KIT Therapies

Overexpression or mutation of KIT protein is closely related to the occurrence of cancer. Currently, research on mutated KIT receptors contributes to the discovery of new KIT-based therapies for drug-resistant tumor cells in cancer therapy. Fortunately, there is already an anti-KIT antibody-drug conjugate that has been shown to exhibit antitumor activity both in vitro and in vivo.

Anti-KIT Neutralizing Antibody

With an advanced platform and a well-trained team, Creative Biolabs is pleased to provide a wide range of monoclonal and neutralizing antibodies that react with KIT to customers around the world. Our antibodies are purified through affinity chromatography. Additionally, SDS-PAGE and SEC-HPLC analytical tests were performed to ensure the purity and integrity of the antibodies. We are confident that our diverse and high-quality KIT antibody products can satisfy your different experimental purposes. If you have any technical concerns about our KIT antibody products, please contact us in time.

REFERENCES

Katagiri, Seiichiro, et al. "Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia." International Journal of Molecular Sciences 23.9 (2022): 4694.
Kim, Minji, Kush Savsani, and Sivanesan Dakshanamurthy. "A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia." Pharmaceuticals 16.7 (2023): 932.
Distributed under Open Access license CC BY 4.0, without modification.

Show More Close